Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to address serious bacterial infections, including C. difficile infection and acute myeloid leukemia-associated infections.
Acurx said a scientific poster at the International C. difficile Symposium showed superior in vitro kill kinetics for ibezapolstat versus vancomycin and fidaxomicin in C. difficile and vancomycin-resistant Enterococcus co-cultures.
PR Newswire reports Acurx Pharmaceuticals received FDA conditional acceptance and a USPTO trademark allowance for the company's brand name for ibezapolstat.